Neurodegenerative Diseases Drugs Market Report and Forecast 2025-2034
Description
The neurodegenerative diseases drugs market was valued at USD 44.69 Billion in 2024, driven by rising prevalence of neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease across the 8 major markets The market is expected to grow at a CAGR of 7.10% during the forecast period of 2025-2034 to achieve a value of USD 88.74 Billion by 2034.
Neurodegenerative Diseases Drugs Market Overview
Neurodegenerative diseases drugs are the medications aimed at treating neurodegenerative diseases such as Alzheimer’s, multiple sclerosis, and spinal muscular atrophy, among others. These types of drugs can be taken orally, intravenously, or through the skin. Neurodegenerative diseases refer to those diseases and conditions that are caused by a loss in performance or structure of neurons, due to neurodegeneration process. As there is currently no cure for neurodegenerative diseases and based on the disease, slowing the progression can also be difficult, the importance of neurodegenerative diseases drugs in combating symptoms is vital. Early and regular intake of neurodegenerative diseases drugs can help control the disease.
The market value is expected to be impacted by increasing drug approvals by affluent regulatory authorities such as United States FDA to bring effective and affordable treatment alternatives for patients. In addition, integration of artificial intelligence algorithms into drug development, intended to improve efficacy and streamline the drug development process is another factor contributing to market growth.
Neurodegenerative Diseases Drugs Market Growth Drivers
Rising Prevalence of Neurodegenerative Diseases
Neurodegenerative disorders encompass several chronic conditions such as Alzheimer's disease and other memory disorders, ataxia, Huntington's disease, Parkinson's disease, multiple sclerosis, and multiple system atrophy, among others. In United States, Parkinson’s disease incidence rate witnessed steep growth, leading to diagnosis of nearly 90,000 people in the region. In addition, around 6.7 million Americans aged 65 or above are affected from Alzheimer’s disease, with the prevalence rate expected to reach 13.8 million by 2060. Hence, there is increased emphasis on managing the rising burden of neurodegenerative disorders, leading to high demand of drugs and therapeutic alternatives.
Surge in Collaborations Between Leading Companies to Meet Rising Neurodegenerative Diseases Drugs Market Demand
In November 2023, Charles River Laboratories and Aitia collaborated to leverage Logica, Charles River’s artificial intelligence (AI)-powered drug solution platform and develop treatment alternatives for neurological indications, including Alzheimer’s, Parkinson’s, and Huntington’s diseases. As per the terms of agreement, the two companies are expected to combine their expertise in drug research and development, while incorporating modern technologies to create precise and efficient drugs. Such partnerships are expected to shape the market landscape significantly in the forecast period.
Neurodegenerative Diseases Drugs Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Increasing Drug Approvals from Regulatory Authorities
The growing approvals of newly developed drugs by regulatory authorities, such as the United States’ FDA are key trends in the neurodegenerative disease drugs market. Regulatory approval helps support the wider access of these drugs, enabling more patients to use them.
Preference for Personalized Medicine
With a better understanding of human physiology and technical advancements, there has been a rising inclination towards personalized medicine alternatives. Advances in biomarkers and genomics is enabling the creation of customized drugs based on an individual’s generic makeup, boosting the efficacy of treatment.
Growth in Fundings and Investments
The market is witnessing a surge in investments and fundings to boost neurodegenerative drug research. Non-profit organizations, governments and private investors are offering grants and investments to upcoming pharmaceutical companies and research institutions, with an aim to introduce new drugs in the market.
Focus on Early Diagnosis
As there is currently no cure for neurodegenerative diseases and based on the disease, slowing the progression can also be difficult, the importance of neurodegenerative diseases drugs in combating symptoms is vital. Early and regular intake of neurodegenerative diseases drugs can help control the disease.
Neurodegenerative Diseases Drugs Market Segmentation
The EMR’s report titled “Neurodegenerative Diseases Drugs Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class Germany
France
Italy
Spain
United Kingdom
Market Segmentation Based on Indication is Anticipated to Witness Substantial Growth
Based on indication disease, the market breakup includes multiple sclerosis, Parkinson’s disease, Alzheimer's disease, spinal muscular atrophy (SMA) and others.The Alzheimer's disease segment, based on disease indication, holds a significant share in the neurodegenerative disease drugs market, owing to the high prevalence of this disease among the elderly. The increasing geriatric population is leading to an escalation of the cases of Alzheimer’s disease which is in turn boosting the sale of drugs intended towards treating cognitive manifestations related to this disease.
Meanwhile, cases of Parkinson’s disease are also escalating worldwide, supported by growing awareness and faster diagnoses. Over the forecast period, the increase in awareness about these diseases, along with early diagnostic tools and protocols are expected to fuel the neurodegenerative diseases drugs market growth.
Global Neurodegenerative Diseases Drugs Market Analysis by Region
Based on region, the market report covers United States, EU-4 (Germany, France, Italy and Spain), United Kingdom, Japan and India. The United States is expected to lead the market share in the forecast period, driven by a favorable regulatory landscape, leading to increased number of drug approvals. In addition, the presence of key healthcare and pharmaceutical companies in the region also boosts the market value. For instance, in January 2023, FDA granted approval to Eisai’s Leqembi (lecanemab-irmb) for treatment of Alzheimer's disease under the accelerated approval pathway. The results were based on Phase 3 randomized, controlled clinical trial, that confirmed the drug's clinical benefits.
In EU-4 and United Kingdom is estimated to hold a significant market share in the forecast period, driven by the emergence of new biotechnology companies in the region. There has been an influx of investments and fundings to support upcoming talent that has the potential to incorporate latest techniques into drug development processes. In June 2023, BIOS Health, a healthcare startup raised USD 20 million from various private investors and expects to utilize the amount in precision trials for neurological therapies.
Countries like Japan and India are emerging markets for neurodegenerative diseases, with the growing awareness leading to early diagnosis and treatment. In addition, increased investments from governments to develop medical infrastructure is projected to boost rapid growth in the coming years.
Leading Players in the Neurodegenerative Diseases Drugs Market
The key features of the market report include patent analysis, clinical trial analysis, grant analysis, funding, and investment analysis as well as strategic initiatives such as recent joint ventures, along with partnerships and collaborations by the leading players. The major companies in the market are as follows:
Pfizer, Inc.
It is one of the largest pharmaceutical manufacturers across the world. This company was founded in the year 1849 and is currently headquartered in New York, United States. Pfizer, Inc. produces medications, drugs, and vaccines, aimed towards battling chronic diseases. It is known for the development of remarkable breakthroughs in the field of pharmaceuticals.
Merck KGaA
Founded in the year 1668 and currently headquartered in Darmstadt, Germany, Merck KGaA is a leading science and technology company, and one of the oldest pharmaceutical companies around the world. It delivers progressive treatment solutions, personalised treatments, and healthcare products for oncology, endocrinology, fertility, neurology, immunology, and general medicine. Apart from healthcare, Merck also specialises in electronics and life sciences.
Novartis AG
Based in Basel, Switzerland, it was founded in the year 1997 and currently innovates and sells medicines and drugs to cure various chronic diseases. Novartis AG has been structured into two companies namely, Innovative Medicines and Sandoz. The company is also a prominent player in the field of science and technology.
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals, an American health care company is known for its therapeutics for Parkinson’s disease psychosis and Rett syndrome. The company is committed to address unmet needs in rare diseases and has several drugs in pipeline for various neurodegenerative diseases.
Other players in the market include Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Neuronity Therapeutics, Inc., Arkuda Therapeutics Inc., NeuroX1 Inc., and Annovis Bio, Inc.
Key Questions Answered in the Neurodegenerative Diseases Drugs Market Report
Neurodegenerative Diseases Drugs Market Overview
Neurodegenerative diseases drugs are the medications aimed at treating neurodegenerative diseases such as Alzheimer’s, multiple sclerosis, and spinal muscular atrophy, among others. These types of drugs can be taken orally, intravenously, or through the skin. Neurodegenerative diseases refer to those diseases and conditions that are caused by a loss in performance or structure of neurons, due to neurodegeneration process. As there is currently no cure for neurodegenerative diseases and based on the disease, slowing the progression can also be difficult, the importance of neurodegenerative diseases drugs in combating symptoms is vital. Early and regular intake of neurodegenerative diseases drugs can help control the disease.
The market value is expected to be impacted by increasing drug approvals by affluent regulatory authorities such as United States FDA to bring effective and affordable treatment alternatives for patients. In addition, integration of artificial intelligence algorithms into drug development, intended to improve efficacy and streamline the drug development process is another factor contributing to market growth.
Neurodegenerative Diseases Drugs Market Growth Drivers
Rising Prevalence of Neurodegenerative Diseases
Neurodegenerative disorders encompass several chronic conditions such as Alzheimer's disease and other memory disorders, ataxia, Huntington's disease, Parkinson's disease, multiple sclerosis, and multiple system atrophy, among others. In United States, Parkinson’s disease incidence rate witnessed steep growth, leading to diagnosis of nearly 90,000 people in the region. In addition, around 6.7 million Americans aged 65 or above are affected from Alzheimer’s disease, with the prevalence rate expected to reach 13.8 million by 2060. Hence, there is increased emphasis on managing the rising burden of neurodegenerative disorders, leading to high demand of drugs and therapeutic alternatives.
Surge in Collaborations Between Leading Companies to Meet Rising Neurodegenerative Diseases Drugs Market Demand
In November 2023, Charles River Laboratories and Aitia collaborated to leverage Logica, Charles River’s artificial intelligence (AI)-powered drug solution platform and develop treatment alternatives for neurological indications, including Alzheimer’s, Parkinson’s, and Huntington’s diseases. As per the terms of agreement, the two companies are expected to combine their expertise in drug research and development, while incorporating modern technologies to create precise and efficient drugs. Such partnerships are expected to shape the market landscape significantly in the forecast period.
Neurodegenerative Diseases Drugs Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Increasing Drug Approvals from Regulatory Authorities
The growing approvals of newly developed drugs by regulatory authorities, such as the United States’ FDA are key trends in the neurodegenerative disease drugs market. Regulatory approval helps support the wider access of these drugs, enabling more patients to use them.
Preference for Personalized Medicine
With a better understanding of human physiology and technical advancements, there has been a rising inclination towards personalized medicine alternatives. Advances in biomarkers and genomics is enabling the creation of customized drugs based on an individual’s generic makeup, boosting the efficacy of treatment.
Growth in Fundings and Investments
The market is witnessing a surge in investments and fundings to boost neurodegenerative drug research. Non-profit organizations, governments and private investors are offering grants and investments to upcoming pharmaceutical companies and research institutions, with an aim to introduce new drugs in the market.
Focus on Early Diagnosis
As there is currently no cure for neurodegenerative diseases and based on the disease, slowing the progression can also be difficult, the importance of neurodegenerative diseases drugs in combating symptoms is vital. Early and regular intake of neurodegenerative diseases drugs can help control the disease.
Neurodegenerative Diseases Drugs Market Segmentation
The EMR’s report titled “Neurodegenerative Diseases Drugs Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
- Immunomodulator
- Interferons
- Decarboxylase Inhibitors
- Dopamine Agonists
- Others
- Oral
- Parenteral
- Transdermal
- Multiple Sclerosis
- Parkinson’s Disease
- Alzheimer's Disease
- Spinal Muscular Atrophy (SMA)
- Others
- United States
- EU-4 and the United Kingdom
- Japan
- India
Market Segmentation Based on Indication is Anticipated to Witness Substantial Growth
Based on indication disease, the market breakup includes multiple sclerosis, Parkinson’s disease, Alzheimer's disease, spinal muscular atrophy (SMA) and others.The Alzheimer's disease segment, based on disease indication, holds a significant share in the neurodegenerative disease drugs market, owing to the high prevalence of this disease among the elderly. The increasing geriatric population is leading to an escalation of the cases of Alzheimer’s disease which is in turn boosting the sale of drugs intended towards treating cognitive manifestations related to this disease.
Meanwhile, cases of Parkinson’s disease are also escalating worldwide, supported by growing awareness and faster diagnoses. Over the forecast period, the increase in awareness about these diseases, along with early diagnostic tools and protocols are expected to fuel the neurodegenerative diseases drugs market growth.
Global Neurodegenerative Diseases Drugs Market Analysis by Region
Based on region, the market report covers United States, EU-4 (Germany, France, Italy and Spain), United Kingdom, Japan and India. The United States is expected to lead the market share in the forecast period, driven by a favorable regulatory landscape, leading to increased number of drug approvals. In addition, the presence of key healthcare and pharmaceutical companies in the region also boosts the market value. For instance, in January 2023, FDA granted approval to Eisai’s Leqembi (lecanemab-irmb) for treatment of Alzheimer's disease under the accelerated approval pathway. The results were based on Phase 3 randomized, controlled clinical trial, that confirmed the drug's clinical benefits.
In EU-4 and United Kingdom is estimated to hold a significant market share in the forecast period, driven by the emergence of new biotechnology companies in the region. There has been an influx of investments and fundings to support upcoming talent that has the potential to incorporate latest techniques into drug development processes. In June 2023, BIOS Health, a healthcare startup raised USD 20 million from various private investors and expects to utilize the amount in precision trials for neurological therapies.
Countries like Japan and India are emerging markets for neurodegenerative diseases, with the growing awareness leading to early diagnosis and treatment. In addition, increased investments from governments to develop medical infrastructure is projected to boost rapid growth in the coming years.
Leading Players in the Neurodegenerative Diseases Drugs Market
The key features of the market report include patent analysis, clinical trial analysis, grant analysis, funding, and investment analysis as well as strategic initiatives such as recent joint ventures, along with partnerships and collaborations by the leading players. The major companies in the market are as follows:
Pfizer, Inc.
It is one of the largest pharmaceutical manufacturers across the world. This company was founded in the year 1849 and is currently headquartered in New York, United States. Pfizer, Inc. produces medications, drugs, and vaccines, aimed towards battling chronic diseases. It is known for the development of remarkable breakthroughs in the field of pharmaceuticals.
Merck KGaA
Founded in the year 1668 and currently headquartered in Darmstadt, Germany, Merck KGaA is a leading science and technology company, and one of the oldest pharmaceutical companies around the world. It delivers progressive treatment solutions, personalised treatments, and healthcare products for oncology, endocrinology, fertility, neurology, immunology, and general medicine. Apart from healthcare, Merck also specialises in electronics and life sciences.
Novartis AG
Based in Basel, Switzerland, it was founded in the year 1997 and currently innovates and sells medicines and drugs to cure various chronic diseases. Novartis AG has been structured into two companies namely, Innovative Medicines and Sandoz. The company is also a prominent player in the field of science and technology.
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals, an American health care company is known for its therapeutics for Parkinson’s disease psychosis and Rett syndrome. The company is committed to address unmet needs in rare diseases and has several drugs in pipeline for various neurodegenerative diseases.
Other players in the market include Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Neuronity Therapeutics, Inc., Arkuda Therapeutics Inc., NeuroX1 Inc., and Annovis Bio, Inc.
Key Questions Answered in the Neurodegenerative Diseases Drugs Market Report
- What was the neurodegenerative diseases drugs market value in 2023?
- What is the neurodegenerative diseases drugs market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on drug classes?
- What is the market breakup based on route of administration?
- Who is the market segmentation based on disease indication?
- What are the major factors aiding the neurodegenerative diseases drugs market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- What drug class will dominate the market share?
- Which disease indication is expected to have a high market value in the coming years?
- Who are the key players involved in the neurodegenerative diseases drugs market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Neurodegenerative Diseases Drugs Market Overview: 8 Major Markets
- 3.1 Neurodegenerative Diseases Drugs Market Historical Value (2018-2024)
- 3.2 Neurodegenerative Diseases Drugs Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Neurodegenerative Diseases: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Neurodegenerative Diseases Drugs Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Neurodegenerative Diseases Drugs Market Landscape: 8 Major Market*
- 8.1 Neurodegenerative Diseases Drugs Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Neurodegenerative Diseases Drugs Market: Product Landscape
- 8.2.1 Analysis by Drug Class
- 8.2.2 Analysis by Route of Administration
- 8.2.3 Analysis by Disease Indication
- 9 Neurodegenerative Diseases Drugs Market Therapy Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Neurodegenerative Diseases Drugs: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Neurodegenerative Diseases Drugs Market Segmentation: 8 Major Markets
- 12.1 Neurodegenerative Diseases Drugs Market by Drug Class
- 12.1.1 Market Overview
- 12.1.2 Immunomodulator
- 12.1.3 Interferons
- 12.1.4 Decarboxylase Inhibitors
- 12.1.5 Dopamine Agonists
- 12.1.6 Others
- 12.2 Neurodegenerative Diseases Drugs Market by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.2.4 Transdermal
- 12.3 Neurodegenerative Diseases Drugs Market by Disease Indication
- 12.3.1 Market Overview
- 12.3.2 Multiple Sclerosis
- 12.3.3 Parkinson’s Disease
- 12.3.4 Alzheimer's Disease
- 12.3.5 Spinal Muscular Atrophy (SMA)
- 12.3.6 Others
- 12.4 Neurodegenerative Diseases Drugs Market by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Neurodegenerative Diseases Drugs Market (218-2034)
- 13.1 United States Neurodegenerative Diseases Drugs Market Historical Value (2018-2024)
- 13.2 United States Neurodegenerative Diseases Drugs Market Forecast Value (2025-2034)
- 13.3 United States Neurodegenerative Diseases Drugs Market (2018-2034) by Drug Class
- 13.3.1 Market Overview
- 13.3.2 Immunomodulator
- 13.3.3 Interferons
- 13.3.4 Decarboxylase Inhibitors
- 13.3.5 Dopamine Agonists
- 13.3.6 Others
- 13.4 United States Neurodegenerative Diseases Drugs Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Transdermal
- 13.5 United States Neurodegenerative Diseases Drugs Market (2018-2034) by Diseases Indication
- 13.5.1 Multiple Sclerosis
- 13.5.2 Parkinson’s Disease
- 13.5.3 Alzheimer's Disease
- 13.5.4 Spinal Muscular Atrophy (SMA)
- 13.5.5 Others
- 14 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market (218-2034)
- 14.1 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market (2018-2034) by Drug Class
- 14.3.1 Market Overview
- 14.3.2 Immunomodulator
- 14.3.3 Interferons
- 14.3.4 Decarboxylase Inhibitors
- 14.3.5 Dopamine Agonists
- 14.3.6 Others
- 14.4 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market (2018-2034) by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Parenteral
- 14.4.4 Transdermal
- 14.5 EU-4 and United Kingdom Neurodegenerative Diseases Drugs Market (2018-2034) by Disease Indication
- 14.5.1 Multiple Sclerosis
- 14.5.2 Parkinson’s Disease
- 14.5.3 Alzheimer's Disease
- 14.5.4 Spinal Muscular Atrophy (SMA)
- 14.5.5 Others
- 15 Japan Neurodegenerative Diseases Drugs Market
- 15.1 Japan Neurodegenerative Diseases Drugs Market Historical Value (2018-2024)
- 15.2 Japan Neurodegenerative Diseases Drugs Market Forecast Value (2025-2034)
- 15.3 Japan Neurodegenerative Diseases Drugs Market (2018-2034) by Drug Class
- 15.3.1 Market Overview
- 15.3.2 Immunomodulator
- 15.3.3 Interferons
- 15.3.4 Decarboxylase Inhibitors
- 15.3.5 Dopamine Agonists
- 15.3.6 Others
- 15.4 Japan Neurodegenerative Diseases Drugs Market (2018-2034) by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Parenteral
- 15.4.4 Transdermal
- 15.5 Japan Neurodegenerative Diseases Drugs Market (2018-2034) by Disease Indication
- 15.5.1 Multiple Sclerosis
- 15.5.2 Parkinson’s Disease
- 15.5.3 Alzheimer's Disease
- 15.5.4 Spinal Muscular Atrophy (SMA)
- 15.5.5 Others
- 16 India Neurodegenerative Diseases Drugs Market
- 16.1 India Neurodegenerative Diseases Drugs Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Neurodegenerative Diseases Drugs Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Neurodegenerative Diseases Drugs Market (2018-2034) by Drug Class
- 16.3.1 Market Overview
- 16.3.2 Immunomodulator
- 16.3.3 Interferons
- 16.3.4 Decarboxylase Inhibitors
- 16.3.5 Dopamine Agonists
- 16.3.6 Others
- 16.4 India Neurodegenerative Diseases Drugs Market (2018-2034) by Route of Administration
- 16.4.1 Market Overview
- 16.4.2 Oral
- 16.4.3 Parenteral
- 16.4.4 Transdermal
- 16.5 India Neurodegenerative Diseases Drugs Market (2018-2034) by Disease Indication
- 16.5.1 Multiple Sclerosis
- 16.5.2 Parkinson’s Disease
- 16.5.3 Alzheimer's Disease
- 16.5.4 Spinal Muscular Atrophy (SMA)
- 16.5.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Pfizer, Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Mergers and Acquisitions
- 23.2.5 Certifications
- 23.3 Merck KGaA
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Mergers and Acquisitions
- 23.3.5 Certifications
- 23.4 Novartis AG
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Mergers and Acquisitions
- 23.4.5 Certifications
- 23.5 Acadia Pharmaceuticals Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Mergers and Acquisitions
- 23.5.5 Certifications
- 23.6 Teva Pharmaceutical Industries Ltd.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Mergers and Acquisitions
- 23.6.5 Certifications
- 23.7 F. Hoffmann-La Roche Ltd
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 Neuronity Therapeutics, Inc.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Mergers and Acquisitions
- 23.8.5 Certifications
- 23.9 Arkuda Therapeutics Inc
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Mergers and Acquisitions
- 23.9.5 Certifications
- 23.10 NeuroX1 Inc.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Mergers and Acquisitions
- 23.10.5 Certifications
- 23.11 Annovis Bio, Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Mergers and Acquisitions
- 23.11.5 Certifications
- 24 Neurodegenerative Diseases Drugs Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
